TRPC6 and cystic fibrosis: Most interestingly, a drug called roscovitine, which is tested in clinical studies as therapeutic option for a plethora of diseases, acts as a partial corrector of the F508del CFTR protein [139] and recruits TRPC6 translocation to phagosomal membranes, which is able to restore microbicidal function in alveolar macrophages compromised by CF [140].